Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Krystal Biotech, Inc. (KRYS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
77.50+0.50 (+0.65%)
At close: 04:00PM EST
75.17 -2.33 (-3.01%)
After hours: 04:38PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close77.00
Open75.74
Bid30.84 x 800
Ask82.00 x 900
Day's Range75.28 - 79.28
52 Week Range47.67 - 85.11
Volume158,250
Avg. Volume159,003
Market Cap1.995B
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-4.48
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est105.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KRYS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Krystal Biotech, Inc.
    RGNX: Raising target price to $24.00REGENXBIO INC has an Investment Rating of HOLD; a target price of $24.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference

    PITTSBURGH, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the BofA Securities 2022 Biotech SMID Cap Conference, which is taking place virtually from December 7-8. Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and host in

  • GlobeNewswire

    Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference

    PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the Evercore ISI 5th Annual HealthCONx Conference, which is taking place virtually from November 29-December 1. Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and

  • Benzinga

    Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles

    Krystal Biotech Inc's (NASDAQ: KRYS) subsidiary Jeune Aesthetics Inc, announced nine-month durability of effect in the extension cohort of the PEARL-1 study of KB301 to address the underlying biology of aging skin for improvement of fine lines and wrinkles. Ten subjects from the PEARL-1 efficacy cohort were enrolled in the PEARL-1 extension cohort, an open-label study to assess the duration of effect below the zygomatic arch (the lower cheek area). The extension cohort enrolled subjects who had

Advertisement
Advertisement